ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights August 11, 2018/0 Comments/in Uncategorized /by Steve Launch of clinical development of avacopan in Hidradenitis Suppurativa (HS), an orphan dermatological disease, remains on track for 2018 –. Source link Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on Google+ (Opens in new window) Related https://higenix.com/wp-content/uploads/2018/09/higenix-hs-treatment.png 0 0 Steve https://higenix.com/wp-content/uploads/2018/09/higenix-hs-treatment.png Steve2018-08-11 10:17:422018-08-11 10:17:42ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights
Leave a Reply
Want to join the discussion?Feel free to contribute!